Loading…
Employees: 804
Size Shaanxi Kanghui Pharmaceutical Co (603139.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $466M, the 4035th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥29.16 on 6 Nov 2026.
Performance Over six months the shares fell 19.7%, against -16.4% for the median peer and -16.4% for the China market (cap-weighted) — 10th lowest of 20 in its peer set.
Growth Revenue fell 21.1% over the last twelve months (peer median -3.4%); the operating margin is -68.0% (peer median 2.3%).
Valuation It trades at 9.0× enterprise value to sales against a peer median of 4.4× (8th most expensive of 21).
Capital Return on invested capital runs 23.7 points below its cost of capital (7.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥429M | CN¥469M | CN¥559M | CN¥672M | CN¥491M |
| Revenue growth | — | -16% | -17% | +37% | — |
| Gross profit | CN¥109M | CN¥100M | CN¥150M | CN¥174M | CN¥185M |
| EBITDA | -CN¥223M | -CN¥79.8M | -CN¥7.11M | CN¥37.0M | CN¥22.6M |
| Net income | -CN¥284M | -CN¥333M | -CN¥89.6M | -CN¥26.2M | -CN¥63.1M |
| Free cash flow | -CN¥117M | -CN¥32.3M | -CN¥8.74M | -CN¥144M | -CN¥82.2M |
| Capital expenditure | CN¥127M | CN¥15.5M | CN¥46.7M | CN¥72.4M | CN¥138M |
| Total debt | CN¥732M | CN¥706M | CN¥630M | CN¥674M | CN¥555M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603139.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -15.4% | -11.3% | 7th lowest of 20 |
| 6-month return | -19.7% | -16.4% | 10th lowest of 20 |
| Distance from 52-week high | -37.9% | -40.7% | 10th highest of 20 |
| Revenue growth (TTM) | -21.1% | -3.4% | 2nd lowest of 21 |
| Operating margin | -68.0% | 2.3% | 4th lowest of 21 |
| EV / Sales | 9.0× | 4.4× | 8th most expensive of 21 |
| ROIC minus cost of capital | -23.7 pp | -2.5 pp | 2nd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $466M | -20% | -21% | -68% | 9.0× | n/a | n/a |
| Evonile Pharma EVONILE.NS | India | $466M | n/a | -5% | 12% | 14.5× | 46.5% | -1.5% |
| Teyi Pharmaceutical 002728.SZ | China | $465M | -9% | -7% | 7% | 3.5× | 26.6% | +8.0% |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $467M | -13% | -5% | -29% | 4.5× | n/a | n/a |
| Shanghai Jiaoda Onlly 600530.SS | China | $464M | -22% | -2% | -2% | 10.4× | 33.5% | -0.9% |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $464M | -30% | +14% | 5% | 2.4× | 2.5% | -1.3% |
| Zhejiang Chengyi Pharmaceutical 603811.SS | China | $463M | -21% | +7% | 19% | 3.6× | 7.1% | +1.3% |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $470M | -39% | +35% | 4% | 1.2× | n/a | n/a |
| Kexing Biopharm 688136.SS | China | $470M | -38% | -14% | -12% | 3.1× | n/a | n/a |
| Cachet Pharmaceutical 002462.SZ | China | $471M | -22% | -14% | 0% | 0.2× | -8.9% | -3.4% |
| YungShin Global 3705.TW | Taiwan | $474M | +7% | -8% | 15% | 1.9× | -4.9% | +0.7% |
| Pulike Biological Engineering 603566.SS | China | $475M | -22% | -9% | 5% | 2.5× | 5.7% | +3.3% |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $476M | +7% | -17% | -28% | 11.5× | n/a | n/a |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $476M | -10% | +40% | 13% | 11.1× | 44.5% | +1.0% |
| Beijing Foyou Pharma 601089.SS | China | $455M | -24% | +5% | 10% | 0.2× | n/a | n/a |
| Gufic Biosciences GUFICBIO.NS | India | $454M | +44% | +17% | 14% | 4.4× | n/a | n/a |
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $477M | +62% | +10,947% | -194% | 132.2× | n/a | n/a |
| CytomX Therapeutics CTMX | United States | $477M | -45% | -87% | -477% | 8.3× | n/a | n/a |
| Aquestive Therapeutics AQST | United States | $454M | -16% | +13% | -114% | 10.5× | n/a | n/a |
| Alpha Teknova TKNO | United States | $482M | +104% | +12% | -35% | 11.3× | n/a | n/a |
| Shanghai Fudan Forward S&T 600624.SS | China | $450M | -4% | -14% | -34% | 6.0× | n/a | n/a |